NDA acceptance with Priority Review and no AdCom is a strong positive signal. The PDUFA date of Nov 30, 2026 provides a clear catalyst. ASCO presentation on May 30 may drive near-term volatility.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 28 $35.38entry
- T+1 · 6mo ago −1.19%α −1.43% · $34.96
- T+5 · 6mo ago −8.82%α −8.77% · $32.26
- T+20 · 5mo ago +7.69%α +10.83% · $38.10
- T+60 · 3mo ago +3.82%α +2.08% · $36.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cogent Biosciences announced FDA acceptance of its NDA for bezuclastinib in combination with sunitinib for GIST, with Priority Review and a PDUFA date of November 30, 2026. The Phase 3 PEAK trial showed a median PFS of 16.5 months vs 9.2 months (HR=0.50, p<0.0001) and a 46% ORR vs 26% for sunitinib alone. This is a major regulatory milestone for a first-in-class combination that could transform second-line GIST treatment, with no advisory committee planned and no identified review issues.
Key Facts
- FDA accepted NDA for bezuclastinib + sunitinib in GIST with Priority Review; PDUFA date November 30, 2026
- Phase 3 PEAK trial: median PFS 16.5 months (combination) vs 9.2 months (sunitinib alone); HR=0.50 (95% CI: 0.39-0.65, p<0.0001)
- ORR 46% for combination vs 26% for sunitinib monotherapy in imatinib-resistant patients
- No advisory committee planned; FDA communicated no potential review issues identified
- Full PEAK results to be presented at ASCO oral session on May 30, 2026
- Company preparing for launches in both GIST and systemic mastocytosis later this year
- Expanded Access Programs established for U.S. patients with GIST or SM
Financial Impact
First approval for a novel KIT inhibitor combination in GIST; potential peak sales in the hundreds of millions to billions given GIST prevalence and clear superiority over standard of care
Risk Factors
- FDA could issue a Complete Response Letter at PDUFA despite current positive signals
- Hepatic safety signals (ALT/AST elevations) could become a review focus
- Commercial launch execution risk in both GIST and SM
- Overall survival data remains immature; negative OS readout could limit label expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302753 |
Track record
13 reports on COGT
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Viewing Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers